Rheumatic disorder – European Clinical Trials Information Network

Study of cardiovascular disease prevention using carotid ultrasound in patients with inflammatory rheumatic diseases treated with amlodipine, atorvastatin, rosuvastatin, ezetimibe and bempedoic acid

Wed, 29 Apr 2026 15:06:50 +0000

This clinical trial focuses on preventing cardiovascular disease in people who have chronic inflammatory rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, or systemic lupus erythematosus. The study aims to evaluate whether using carotid ultrasound helps identify and treat patients who may be at high risk for heart and blood vessel problems.

The study uses several medications to help lower cholesterol and protect the heart, including combinations of amlodipine and atorvastatin, as well as rosuvastatin with ezetimibe. Another medication being tested is bempedoic acid. These medications are taken by mouth daily over a period of up to 48 months.

The researchers will monitor participants to see if they develop any serious heart or blood vessel problems, such as heart attacks, strokes, or other complications that require hospital treatment. This will help determine if using ultrasound scanning to guide treatment decisions leads to better outcomes compared to current standard treatment approaches.

Study of Janus kinase inhibitor dose reduction in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis who have achieved low disease activity

Wed, 29 Apr 2026 15:06:49 +0000

This study focuses on patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis who are currently taking medications called Janus Kinase inhibitors (JAKi). These medications include filgotinib (Jyseleca), tofacitinib (Xeljanz), upadacitinib (Rinvoq), and baricitinib (Olumiant), which are used to treat inflammatory conditions affecting joints and the spine.

The purpose of this research is to determine if gradually reducing the dose of these medications is as effective as continuing with the current dose in patients whose disease is well-controlled. The study will examine patients who have maintained low disease activity or whose symptoms have been in remission for at least 6 months while taking these medications.

During the 12-month study period, participants will be monitored for disease activity, quality of life, and any side effects. The study will track how well the joints function, any disease flare-ups, and other health-related factors. Researchers will also measure medication levels in the blood and examine immune system cells to better understand how these treatments work.

Study on Immune Response to Recombinant Zoster Vaccine in Rheumatic Disease Patients Using Baricitinib, Tofacitinib, or Methotrexate

Wed, 29 Apr 2026 15:05:04 +0000

This clinical trial focuses on patients with rheumatic diseases, which are conditions that cause pain and inflammation in the joints and muscles. The study will explore the effects of a vaccine called the recombinant zoster vaccine (RZV), which is designed to protect against shingles, a painful rash caused by the same virus that causes chickenpox. The trial will involve patients who are taking medications known as JAK inhibitors (such as baricitinib, tofacitinib, filgotinib, and upadacitinib) either alone or in combination with methotrexate, as well as those taking methotrexate by itself. These medications are used to manage rheumatic diseases by reducing inflammation and suppressing the immune system.

The purpose of the study is to assess how well the immune system responds to the RZV vaccine in these patients. The study will monitor the levels of specific antibodies and immune cells that are expected to increase after vaccination. Participants will receive two doses of the vaccine, and their immune response will be measured one month after the second dose. The study will also track any symptoms that occur after vaccination and examine changes in immune system markers over time.

Throughout the study, researchers will collect information on how the immune system reacts to the vaccine and how long the response lasts. They will also compare the immune response to the RZV vaccine with responses to COVID-19 vaccines in similar patients. The study is expected to provide valuable insights into the effectiveness of the RZV vaccine in people with rheumatic diseases who are taking immunosuppressive medications.

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Wed, 29 Apr 2026 15:04:11 +0000

This clinical trial is focused on studying a group of diseases known as Systemic Autoimmune Rheumatic Diseases that are associated with a lung condition called Interstitial Lung Disease (SARD-ILD). These diseases can cause inflammation and scarring in the lungs, leading to breathing difficulties. The study is testing a new treatment called nerandomilast, which is being developed to help manage lung fibrosis, a type of lung scarring, in people with these conditions.

The purpose of the study is to evaluate the effectiveness and safety of nerandomilast over a period of 26 weeks. Participants in the study will receive either the active medication, nerandomilast, or a placebo, which looks like the medication but does not contain the active ingredient. The study will monitor changes in lung health using a special type of imaging called high-resolution computed tomography (HRCT), which provides detailed pictures of the lungs. The study will also track any side effects and changes in symptoms such as cough and shortness of breath.

Participants will be involved in the study for about six months, during which they will have regular check-ups and assessments to monitor their lung condition and overall health. The study aims to provide valuable information on whether nerandomilast can improve lung function and quality of life for people with SARD-ILD. This research could lead to new treatment options for those affected by these challenging conditions.

Study on the Safety of Faster Infusions for Cancer Patients Using Trastuzumab, Bevacizumab, and Atezolizumab

Wed, 29 Apr 2026 15:01:58 +0000

This clinical trial is focused on studying the safety of shortened infusion times for various cancer treatments known as monoclonal antibodies. These treatments include nivolumab, pembrolizumab, ipilimumab, bevacizumab, trastuzumab, durvalumab, atezolizumab, and rituximab. Monoclonal antibodies are a type of protein made in the lab that can bind to substances in the body, including cancer cells. The purpose of the study is to determine how often and how severe infusion-related reactions occur when these medications are given more quickly than usual.

Participants in the study will receive one of the mentioned treatments through an intravenous infusion, which means the medication is delivered directly into a vein. The study will observe and record any reactions that occur during these faster infusions. These reactions can include symptoms like fever, chills, or rash, which are sometimes experienced when the body responds to the medication. The study will compare these reactions to those recorded in past treatments where the infusions were given at a standard pace.

The study will continue over a period of time, with participants receiving their treatments and being monitored for any side effects. The goal is to gather information on whether these faster infusions are safe and to understand the experiences of patients undergoing these treatments. This information could help improve the way these cancer therapies are administered in the future, potentially making them more convenient for patients. The study will also look at other factors such as the effectiveness of the treatment and the overall experience of the patients involved.